Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Panic-Proof Portfolio (Stockchase Research) and Gordon Reid commented about whether MSFT-Q, GFF-N, C-N, CVS-N, FSLR-Q, TOL-N, INTC-Q, VZ-N, ADBE-Q, MRK-N, WMT-N, LLY-N, AMGN-Q, ABBV-N, V-N, J-N, GOOG-Q, PLTR-Q, HD-N, LOW-N, UBER-N, CRWD-Q, NFLX-Q, MMM-N, BAC-N, BLK-N, IVZ-N, NWN-N, GDEN-Q, MRD-T, UNP-N, RNR-N, MRC-T, VEON-Q, ROIV-Q are stocks to buy or sell.
- Page 1/3
- Next Page
We reiterate VEON as a TOP PICK. The company provides mobile and internet service to 160 million European customers, including providing important infrastructure in Ukraine. We like that cash reserves are growing, while debt is aggressively retired. It trades at 2.2x book, 7x earnings, and supports a 36% ROE. We continue to recommend a stop at $25, looking to achieve $38 -- upside potential of 31%. Yield 0%
(Analysts’ price target is $38.00)With inflation pressures beginning to ease and interest rates plateauing, we again reiterate MRC as a TOP PICK. Management sees resiliency in commercial and multi-family properties going forward. It trades at 6x earnings, under book and the company has built cash reserves, while aggressively retiring debt. We continue to recommend a stop at $103, looking to achieve $140 -- upside potential of 17%. Yield 0.5%
(Analysts’ price target is $140.00)What's key to a soft landing is that the US economy is holding market up and the job market fairly constructive. In Canada, the inflation number was also good. The risk to the market is that we don't get a soft landing. The market has priced in a soft landing already, possible but unlikely. AI will probably take us to places we can't imagine, just like old mainframe computers did and some lacked the imagination to see their potential.
Wait. Don't enter this now. Wants to see more clarity. Shares are climbing after a long malaise and they have a new CEO. But hey have legacy problems with a chemical and a huge lawsuit, and the noise suppression technology lawsuit. These types of companies do turn around, but he'd rather pay more for more certainty.
After announcing positive reports in two important autoimmune drugs, we again reiterate ROIV as a TOP PICK. It trades at 2x earnings, under 2x book and supports a robust return on equity. We like that cash reserves are growing, while debt is retired. We recommend trailing up the stop (from $9:50) to $10.50, looking to achieve $16.00 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $17.06)